GT Biopharma Inc. Common Stock (GTBP)

Price$0.44

Value ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-52.69%

Price vs S&P 500 (4W)16.32%

VGM Score26.27

Market Capitalization$15.74M

All Metrics

Book Value / Share (Quarterly)$0.22

P/TBV (Annual)52.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-52.58%

Gross Margin (TTM)36.51%

Net Profit Margin (TTM)-26209.52%

EPS (TTM)$-10.65

10-Day Avg Trading Volume1.90M

EPS Excl Extra (TTM)$-10.65

EPS (Annual)$-6.94

Dividend / Share (Annual)$0.02

ROI (Annual)-101.62%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-26774.13%

Cash / Share (Quarterly)$0.25

ROA (Last FY)-311.01%

EBITD / Share (TTM)$-1.07

ROE (5Y Avg)-569.56%

Operating Margin (TTM)-8623.81%

Cash Flow / Share (Annual)$-0.51

P/B Ratio2.08x

P/B Ratio (Quarterly)1.70x

Net Income / Employee (Annual)$-13,162,000

EV / Revenue (TTM)108.17x

Net Interest Coverage (TTM)-80.82x

ROA (TTM)-646.21%

EPS Incl Extra (Annual)$-6.94

Current Ratio (Annual)3.50x

Quick Ratio (Quarterly)3.97x

3-Month Avg Trading Volume1.25M

52-Week Price Return-83.85%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.24

P/S Ratio (Annual)582.88x

Asset Turnover (Annual)0.50x

52-Week High$3.85

Operating Margin (5Y Avg)-10668.30%

EPS Excl Extra (Annual)$-6.94

26-Week Price Return-44.77%

Quick Ratio (Annual)3.25x

13-Week Price Return-7.15%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.14x

Enterprise Value$6.81M

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-84.55%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)2.71x

Pretax Margin (Annual)-79485.19%

Cash / Share (Annual)$0.27

3-Month Return Std Dev129.92%

Gross Margin (5Y Avg)26.61%

Net Income / Employee (TTM)$-47,734,000

ROE (Last FY)-101.62%

Net Interest Coverage (Annual)-208.37x

EPS Basic Excl Extra (Annual)$-6.94

P/FCF (TTM)1430.71x

Receivables Turnover (TTM)3.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.65

Receivables Turnover (Annual)3.05x

ROI (TTM)-321.96%

P/S Ratio (TTM)249.81x

Pretax Margin (5Y Avg)-26782.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.36

Price vs S&P 500 (52W)-108.21%

Year-to-Date Return-44.42%

5-Day Price Return-1.27%

EPS Normalized (Annual)$-6.94

ROA (5Y Avg)-233.96%

Net Profit Margin (Annual)-79485.19%

Month-to-Date Return-8.74%

Cash Flow / Share (TTM)$-0.27

EBITD / Share (Annual)$-7.57

Operating Margin (Annual)-33062.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-352.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.65

P/TBV (Quarterly)52.56x

P/B Ratio (Annual)1.44x

Inventory Turnover (TTM)2.71x

Pretax Margin (TTM)-26238.10%

Book Value / Share (Annual)$0.23

Price vs S&P 500 (13W)-15.40%

Beta0.88x

P/FCF (Annual)46.02x

Revenue / Share (TTM)$0.00

ROE (TTM)-321.96%

52-Week Low$0.26

vGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.11est. -0.08

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GTBPGT Biopharma Inc. Common Stock	D	—	D	$0.44
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology drugs using its proprietary TriKE platform. The platform's therapeutic candidates are designed to treat hematologic malignancies, sarcoma, and solid tumors. The company is advancing these novel therapies toward commercialization in the U.S.